Compare American Superconductor Corporation (AMSC) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Superconductor Corporation vs BioNano Genomics Inc — how do they compare? American Superconductor Corporation trades at $34.73 (market cap $1.74B), while BioNano Genomics Inc trades at $1.17 (market cap $13.77M). The key difference: American Superconductor Corporation is far larger — about 126.4× BioNano Genomics Inc's market cap, and American Superconductor Corporation is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| AMSC | BNGO | |
|---|---|---|
Market Cap | $1.74B | $13.77M |
Sector | Technology | Health |
52-Week High | $66.68 | $4.92 |
52-Week Low | $25.95 | $1.09 |
Enterprise Value | $1.61B | $16.38M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $35.96, down 3.26% today amid bearish technical signals. The stock shows strong fundamentals with recent earnings beats and robust profitability metrics including 44.73% net margin and 35.56% ROE. Revenue grew 34% year-over-year to $299.2 million in 2025, though cash flow trends show negative net cash flow of -$6.9M. Analyst sentiment remains positive with 53% buy ratings despite recent insider selling activity.
The outlook remains cautiously optimistic given strong order backlog growth of 40% and expanding role in AI energy infrastructure. Key risks include valuation concerns at 66.72x EV/EBITDA and acquisition-driven growth versus organic expansion. Earnings momentum and grid technology positioning provide upside potential if execution continues.
BNGO trades at $1.20, up 5.26% today, but technical signals are bearish with moving averages indicating selling pressure. The company reported a net loss of -$26.40M in 2025 despite beating EPS estimates in recent quarters. Recent news highlights leadership changes and growing adoption of its optical genome mapping technology, with 67% year-over-year growth in studies presented at ESHG 2026 (GlobeNewswire, June 18, 2026).
The outlook remains challenged by persistent losses and negative cash flow, though low valuation ratios (P/S 0.31, P/B 0.37) may attract value investors. Analyst sentiment is cautiously optimistic with 57% buy ratings, but execution risks and profitability concerns pose significant headwinds for near-term stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
